« Back to Record
Citation APA

Brandão, M., Hiltermann, J., Wauters, E., Solomon, B., Castanon Alvarez, E., Felip, E., Gort, E., Izumi, H., Kim, D. W., Paz Ares, L., Rohrberg, K., Steinbusch, L., Yoshida, T., Chen, H., Colebrook, S., Achour, I., Origuchi, M., Aroldi, F., & Cho, B. (2023). 1446P Preliminary efficacy and safety of rilvegostomig (AZD2936), a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-pretreated advanced/metastatic non-small-cell lung cancer (NSCLC): ARTEMIDE-01. Annals of oncology, 34, S822-S823. doi:10.1016/j.annonc.2023.09.2477


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/401702

Brandão, M., Hiltermann, J., Wauters, E., Solomon, B., Castanon Alvarez, E., Felip, E., Gort, E., Izumi, H., Kim, D. W., Paz Ares, L., Rohrberg, K., Steinbusch, L., Yoshida, T., Chen, H., Colebrook, S., Achour, I., Origuchi, M., Aroldi, F., & Cho, B. (2023). 1446P Preliminary efficacy and safety of rilvegostomig (AZD2936), a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-pretreated advanced/metastatic non-small-cell lung cancer (NSCLC): ARTEMIDE-01. Annals of oncology, 34, S822-S823. doi:10.1016/j.annonc.2023.09.2477